Plan to merge labs for biofuel research criticized
By David Perlman,
San Francisco Chronicle
| 03. 29. 2012
(03-30) 16:02 PDT RICHMOND -- A plan by Lawrence Berkeley Laboratory to merge its energy labs into a major new research facility in Richmond where scientists would work to develop biofuels through genetic engineering came under fire Wednesday by activists who fear that dangerous new microbes would be created there.
And even if the venture succeeds in transforming plants into biofuels by altering the genes of microbes, the activists argued, the Richmond lab could become an unregulated front for corporate interests and turn millions of acres of croplands used to grow food in underdeveloped countries into huge plantations for energy production.
Their protests reflect deep concerns about the dramatic new science called "synthetic biology," an unfamiliar term that in part involves engineering the genes of microbes to transform worthless plants like switchgrass into potentially unlimited sources of energy. The controversy also recalls an epic time in science nearly 40 years ago when manipulating genes was in its infancy and the public was deeply fearful that some genetically altered "Andromeda Strain" microbe might escape and imperil the world with unknown diseases...
Related Articles
Several recent Biopolitical Times posts (1, 2, 3, 4) have called attention to the alarmingly rapid commercialization of “designer baby” technologies: polygenic embryo screening (especially its use to purportedly screen for traits like intelligence), in vitro gametogenesis (lab-made eggs and sperm), and heritable genome editing (also termed embryo editing or reproductive gene editing). Those three, together with artificial wombs, have been dubbed the “Gattaca stack” by Brian Armstrong, CEO of the cryptocurrency company...
By Adam Feuerstein, Stat | 11.20.2025
The Food and Drug Administration was more than likely correct to reject Biohaven Pharmaceuticals’ treatment for spinocerebellar ataxia, a rare and debilitating neurodegenerative disease. At the very least, the decision announced Tuesday night was not a surprise to anyone paying attention. Approval...
By Lucy Tu, The Guardian | 11.05.2025
Beth Schafer lay in a hospital bed, bracing for the birth of her son. The first contractions rippled through her body before she felt remotely ready. She knew, with a mother’s pit-of-the-stomach intuition, that her baby was not ready either...
By Emily Glazer, Katherine Long, Amy Dockser Marcus, The Wall Street Journal | 11.08.2025
For months, a small company in San Francisco has been pursuing a secretive project: the birth of a genetically engineered baby.
Backed by OpenAI chief executive Sam Altman and his husband, along with Coinbase co-founder and CEO Brian Armstrong, the startup—called...